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bstract
Male breast cancer (MaleBC) is a rare disease, accounting for <1% of all male tumors. During the last few years, there has been an increase
n the incidence of this disease, along with the increase in female breast cancer (FBC). Little is known about the etiology of MaleBC: hormonal,
nvironmental and genetic factors have been reported to be involved in its pathogenesis. Major risk factors include clinical disorders carrying
ormonal imbalances, radiation exposure and, in particular, a positive family history (FH) for BC, the latter suggestive of genetic susceptibility.
are mutations in high-penetrance genes (BRCA1 and BRCA2) confer a high risk of BC development; low-penetrance gene mutations (i.e.
HEK-2) are more common but involve a lower risk increase.
About 90% of all male breast tumors have proved to be invasive ductal carcinomas, expressing high levels of hormone receptors with
vident therapeutic returns.
The most common clinical sign of BC onset in men is a painless palpable retroareolar lump, which should be evaluated by means of
ammography, ultrasonography and core biopsy or fine needle aspiration (FNA).
To date, there are no published data from prospective randomized trials supporting a specific therapeutic approach in MaleBC. Tumor size
ogether with the number of axillary nodes involved are the main prognostic factors and should guide the treatment choice. Locoregional
pproaches include surgery and radiotherapy (RT), depending upon the initial clinical presentation. When systemic treatment (adjuvant,
eoadjuvant and metastatic) is delivered, the choice between hormonal and or chemotherapy (CT) should depend upon the clinical and
iological features, according to the FBC management guidelines. However great caution is required because of high rates of age-related
omorbidities.
2009 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
Male breast cancer (MaleBC) is a rare disease, showing
n increasing incidence trend rising along with that of female
reast cancer (FBC). Even if male and female breast cancers
eem to be similar, with regard to epidemiological aspects,
hey deeply differ because of the lower incidence and later
nset of the former. Little is known about the etiology of
aleBC: hormonal, environmental and genetic factors are
nvolved in the pathogenesis of breast cancer in men as well
s in women. The major risk factor related to MaleBC is a
ositive family history for breast cancer, which indicates a
elevant genetic component. In fact, MaleBC susceptibility
an result from rare mutations in high-penetrance genes con-
erring a high risk, or from more common low-penetrance
enes giving a lower risk increase.
From the clinical and biological point of view, male and
emale breast cancers differ mainly in the frequency of their
istological types and in the expression of hormone receptors
nd of epidermal growth factor receptor 2 (HER2).
In the lack of randomized controlled trials, principles of
anagement of MaleBC are mainly derived from random-
zed trials in female patients (pts). Since it is often late
iagnosed, MaleBC remains a substantial cause of morbidity
nd mortality in men. This last consideration together with
he increasing incidence made it urgent to comprehensively
eview the epidemiological, genetic, histopathological and
linical aspects of MaleBC, including the diagnosis, progno-
is and treatment of the disease.. Epidemiology
In Western countries, MaleBC accounts for <1% of all
ancers in men but its incidence varies greatly in different
a
v
o
[therapy; Hormonal treatment; Survival; Local recurrence
eographical areas and ethnic groups [1,2]. The worldwide
ariation of MaleBC resembles that of FBC, with higher
ates in North America and Europe and lower rates in Asia.
substantial high proportion of MaleBC cases have been
eported in Africa [3]. Although scarce, data from this con-
inent have shown annual MaleBC incidence rates ranging
rom 5 to 15% [4–6]. These relatively high rates have been
ttributed to endemic infectious diseases, such as bilharziosis
nd hepatitis B/C that, by chronic liver infection, may cause
iver damage leading to hyperoestrogenisms. By contrast, the
nnual incidence of MaleBC in Japan is significantly lower
5 per 1,000,000) than the average incidence, comparable
o the lower than average incidence of FBC in this coun-
ry [7]. Recent epidemiological studies indicate that MaleBC
ncidence is rising [8]. The incidence of MaleBC increases
ith age and the bimodal age distribution seen in women
s absent in men, with a peak incidence in the sixth decade
3]. Overall, due to the absence of screening programs in
en, MaleBCs are diagnosed at a more advanced age and
ith a more severe clinical presentation than in women, with
reater tumor size and a more frequent lymphonodal involve-
ent. The mean age at breast cancer diagnosis in males is
3.4 years [9]; in the SEER data, the median ages at diag-
osis of breast cancer were 67 and 62 years in males and
emales, respectively [3]. The mortality rates for MaleBC
ave been shown to remain stable [1], however, survival rates
iffer significantly according to race/ethnicity [10] and are
ot significantly different from those observed in women [3].
n general, the prognosis for male and female patients with
reast cancer is similar. Overall survival rates are lower for
en, but this is due to an older age at diagnosis and moredvanced stage at presentation [11]. Disease-specific sur-
ival rates are higher than overall survival rates due to the
lder average age and deaths from other comorbid diseases
12].
L. Ottini et al. / Critical Reviews in Oncolo
Table 1
Risk factors for male breast cancer.
High risk Hormonal imbalance BRCA2
Testicular or liver damage
Oestrogen intake
Radiation exposure Klinefelter’s syndrome
Breast cancer family history
Moderate/Low riskOccupational exposure BRCA1
Heat
Obesity CHEK2
Cowden syndrome
Suspected risk Occupational exposure AR
Exhaust emissions
Magnetic fields
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factor for the development of MaleBC, with an increase ofAlcohol intake CYP17
. Risk factors
Similar to breast cancer in women, MaleBC is likely
o be caused by the concurrent effects of different risk
actors, including clinical disorders relating to hormonal
mbalances, certain occupational and environmental expo-
ures, and genetic risk factors, for instance a positive family
istory (FH) of breast cancer (BC) and mutations in BC pre-
isposing genes, such as BRCA genes, and possibly others.
nvironmental factors, particularly occupational carcinogen
xposure, might well contribute to MaleBC risk by interact-
ng with genetic factors. We reported a strong association
etween a specific occupation (truck driving) and breast can-
er risk in male carriers of BRCA1/2 mutations [13]. Risk
actors for MaleBC are summarized in Table 1.
.1. Hormonal risk factors
As is the case in female BCs, MaleBCs are highly sensi-
ive to hormonal changes. In particular, hormonal imbalance
etween an excess of estrogen and a deficiency of testos-
erone increases the risk of the disease. This imbalance may
ccur endogenously due to testicular abnormalities, includ-
ng, undescended testes, congenital inguinal hernia, orchitis,
rchiectomy and testicular injury [14]. Liver diseases, such
s cirrhosis, may also result in a hyperestrogenic state [15].
n general, liver damage and disease, caused by the effects of
everal drugs or their metabolites, may affect hepatic func-
ions and lead to hyperestrogenism.
Obesity is one of the most common causes of hyper-
estrogenization in men because of increased peripheral
romatization of androgens. Obesity, in fact, doubles the risk
f breast cancer in men [16–18]. Recently it has been reported
hat first-born male children have a 1.71 times higher risk ofaleBC than their younger brothers, possibly because they
ave been exposed to higher levels of intrauterine estrogen
19].
1
o
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Klinefelter’s syndrome, characterized by 47XXY kary-
type, testicular dysgenesis, gynecomastia, low testosterone
oncentrations and increased gonadotrophins, is strongly
ssociated with MaleBC risk. Individuals with this syndrome
ave a 20–50 times higher risk over the general male popu-
ation [20].
An upset in estrogen or androgen balance is a causal factor
n gynecomastia, which is extremely common in pubescent
oys, may occur in men over the age of 50 and is found in
–38% of male pts affected by BC. However, the incidence
f gynecomastia in MaleBC pts is no higher than in the gen-
ral male population [6]; gynecomastia, therefore, does not
n itself seem to represent a risk factor for MaleBC [17,21].
onditions increasing exposure to estrogen or decreasing
xposure to androgen, such as the exogenous administration
f estrogen to trans-sexuals or the long-term use of antian-
rogens and estrogens in the treatment of prostate cancer,
ave also been implicated as causative factors for MaleBC
22–24].
.2. Occupation and environmental risk factors
As in women, ionizing radiations have been considered
s possible causal cofactors in the etiology of MaleBC [25],
ith a modest positive trend with the increasing number of
-ray examinations performed on chest and adjacent body
reas and with an induction period of at least 20–25 years,
ith a subsequent decrease of risk after the 30 or 40 years
ubsequent to the last exposure.
Occupational exposure to heat and electromagnetic radia-
ion are postulated to be linked to MaleBC risk. A higher
requency of breast cancer is reported in men who have
orked in hot environments, such as blast furnaces, steel
orks, rolling and finishing mills [26], possibly because
ong-lasting exposure to high ambient temperatures can lead
o testicular failure. An increased MaleBC risk has been
bserved in men exposed to high electromagnetic fields [2]
nd a 1.31 relative risk in men with an exposure above the
rst quartile has been reported, although no clear trend of
xposure and risk has emerged [27].
In a few studies, a certain degree of risk has been found
o be associated also to polycyclic aromatic hydrocarbons
PAHs) [2], but the evidence is still too inadequate to draw any
alid conclusions. Moreover, PAHs are usually found in envi-
onments contaminated by other pollutants with mutagenic
ffects, such as nitrogen oxides, nitrosamines and exhaust
umes, making it very difficult to disentangle the effect of
ny single pollutant.
.3. Dietary risk factors
As for women, alcoholic beverages seem to represent a risk6% for each increase of 10 g/day of alcohol intake. More-
ver, strong consumers of alcoholic beverages (more than
0 g/day) present a 6-fold increased OR to develop MaleBC
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hen compared to light consumers (<15 g/day) [28]. The
vailable evidence for other components of diet is rather
carce. The consumption of animal fats and in particular red
eat in relation to the risk of MaleBC has been investigated
n several studies, but the results are still not clear. Incon-
istent findings have also been provided by the evaluation of
he effect of fruit and vegetable intake [28]. Overall, with the
xception of alcohol consumption, dietary factors seem to
lay a marginal role in the etiology of MaleBC.
.4. Family and personal history of cancer
Similar to FBC, a positive FH of BC is associated with
ncreased risk of MaleBC. Data from population-based stud-
es have shown that about 20% of all MaleBC pts have a
istory of BC in a first-degree female relative [17,18,29–31].
n general, a positive FH of either female or male breast can-
er among first-degree relatives confers a 2–3-fold increase in
aleBC risk [17,32–34]. The risk increases with increasing
umbers of first-degree relatives affected and with early onset
n affected relatives. In addition to BC families, MaleBC
ases have also been reported in families with the hered-
tary non-polyposis colorectal cancer (HNPCC) syndrome
35] and Cowden syndrome [36].
A personal history of a second primary tumor is reported
n more than 11% of MaleBC pts [37]. Men diagnosed with
first primary breast cancer have a 16% increased risk of
eveloping a second primary cancer in comparison with the
eneral male population [37]. Data from the SEER program
rom the National Cancer Institute show that a history of
aleBC is associated with a 30-fold increased risk of breast
ancer on the contralateral side [38], which is much higher
han the 2–4-fold increase observed in women [39]. The risk
f a second site-specific cancer is elevated also for gastroin-
estinal cancer, pancreas and prostate carcinomas, melanoma
nd non-melanoma skin tumors [37,40].
a
i
S
able 2
RCA1 and BRCA2 mutations prevalence from studies of male breast cancer patien
tudy Center
ouch et al. Nat Genet 1996 [169] Philadelphia, PA
Friedman et al. Am J Hum Genet 1997 [170] Southern California
,§Thorlacius et al. Am J Hum Genet 1997 [44] Iceland
avraki et al. Br J Cancer 1997 [171] Leeds, UK
araldsson et al. Cancer Res 1998 [172] Sweden
sokay et al. Cancer Res 1999 [173] Hungary
irkkonen et al. Genes Chrom Cancer 1999 [174] Sweden
Sverdlov et al. Genet Test 2000 [175] Israel
wiatkowska et al. Hum Mut 2001 [176] Poland
Basham et al. Breast Cancer Res 2002 [29] Cambridge, UK
rank et al. J Clin Oncol 2002 [42] USA
vans et al. Familial Cancer 2008 [51] Manchester, UK
Chodick et al. Eur J Med Genet 2008 [45] Israel
Ottini et al. Breast Cancer Res 2008 [86] Italy
e: not evaluated.
a Population-based study.
§ Mutational analysis limited to founder mutations.gy/Hematology 73 (2010) 141–155
.5. BRCA1 and BRCA2
MaleBC predisposition can result from germ-line muta-
ions in the high-penetrance BRCA2 (OMIM #6600185) and,
ith lower frequency, BRCA1 (OMIM #113705) genes. The
resence of MaleBC within high-risk BC families indicates
high likelihood of BRCA2 mutations with a frequency
anging from 60 to 76%, whereas BRCA1 mutations fre-
uency ranges from 10 to 16% [41,42]. The frequency
f BRCA1 and BRCA2 mutations are extremely different
n ethnically diverse population- and clinic-based MaleBC
eries, ranging from 4 to 40% for BRCA2 and up to 4% for
RCA1 (Table 2), and resulting higher in the presence of
ounder effects [12,43]. BRCA1 and BRCA2 founder muta-
ions have been identified in specific countries or ethnic
roups, particularly in genetically isolated populations such
s the Icelanders and Ashkenazi Jews. In Iceland, the BRCA2
99del5 founder mutation is involved in 40% of all MaleBC
ases [44]. In Ashkenazi Jews the BRCA1 185delAG and
he BRCA2 6174delT founder mutations found in women are
lso frequent in men. In fact, the combined prevalence of
he BRCA1 and BRCA2 founder mutations among Askenazi
ewish men is slightly higher than for women, due to the
igher frequency of BRCA2 mutations [45]. However, even
n heterogeneous countries, such as Italy, there is evidence of
ounder BRCA1 and BRCA2 mutations in regions that show
micro-homogeneity [46–50]. BRCA2 mutations are cur-
ently considered as the major genetic risk factor for MaleBC,
owever, there is no evidence for a correlation between the
ocation of the mutation within BRCA2 gene and risk of
aleBC. The median age at BC diagnosis among BRCA2
utation carriers is earlier (median, 58.8 years) than that of
egative cases (median, 67.9 years) [29]. Overall, BRCA1
nd BRCA2 mutations are more prevalent in men with a pos-
tive first-degree FH compared with those without [29,51,52].
ince mutations are also identified in MaleBC cases without
ts.
n tested BRCA1 mutation n (%) BRCA2 mutation n (%)
50 ne 7 (14)
54 0 2 (4)
30 ne 12 (40)
28 ne 2 (7.1)
34 ne 7 (21)
18 0 6 (33)
26 0 5 (19)
31 1 (3) 1 (3)
37 ne 4 (11)
94 0 5 (5)
76 8 (10) 14 (18)
64 4 (6) 17 (27)
261 8 (3) 21 (8)
108 2 (2) 8 (7)
Oncology/Hematology 73 (2010) 141–155 145
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Table 3
Age-specific cumulative risk of developing breast cancer for general male
population and male BRCA1 and BRCA2 mutation carriers (%)a.
Age, year General population BRCA1 carrier BRCA2 carrier
30 1.2 × 10−4 1.7 × 10−2 0.18
40 1.9 × 10−3 0.12 1.2
50 8.5 × 10−3 0.3 2.7
60 2.7 × 10−2 0.62 4.7
70 6.7 × 10−2 1.2 6.8
80 0.12 1.8 8.3
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H, from a clinical point of view, predictive genetic testing
s not only beneficial in men from high-risk families but also
mong isolated MaleBC cases.
.6. CHEK2
There is evidence supporting the implication of CHEK2
OMIM #604373), a cell cycle checkpoint kinase that along
ith BRCA1 and BRCA2 plays a role in DNA repair, in
nherited MaleBC predisposition. In particular, it has been
stimated that the CHEK2 1100delC mutation accounts for
% of MaleBC cases and confers approximately a 10-fold
ncrease of BC risk in men lacking BRCA1 and BRCA2
utations [53]. Although this mutation has been strongly
ssociated with the increased MaleBC risk in high-risk BC
amilies, this association is not so clear in MaleBC cases uns-
lected for FH [54–57]. Furthermore, there is evidence that
he contribution of the CHEK2 1100delC variant to MaleBC
redisposition varies from one ethnic group and from one
ountry to another [58].
.7. AR
AR gene (OMIM # 313700), the gene encoding the andro-
en receptor, has been suggested to play a role in MaleBC
redisposition. Germ-line mutations of AR and variation of
he polyglutamine (CAG) repeat within AR exon 1 were found
n MaleBC cases [59], However, these results were not sup-
orted by additional studies [60]. Overall, AR gene mutations
o not seem to contribute significantly to the risk of MaleBC.
.8. CYP17
The CYP17 gene encodes for the cytochrome P450c17
nzyme that is involved in the synthesis of estrogens and
ndrogens. A germ-line variant in the CYP17 promoter region
as found to be associated with an increased MaleBC risk
61]. Overall, a possible role for the CYP17 promoter poly-
orphism in MaleBC risk may be suggested although studies
re not conclusive because of the small sample size analyzed.
. Lifetime risk for male breast cancer
Male carriers of BRCA2 germ-line mutations have a higher
isk of developing BC than men in the general population.
ale BRCA2 mutation carriers have been estimated to have
lifetime risk of 6.9% for developing BC, which is approx-
mately 80–100 times higher than in the general population
62]. The association between BRCA1 germ-line mutations
nd MaleBC risk has proved to be less clear. In a clinically
ased study of BRCA1 mutation carriers, a lifetime risk of
.8% for MaleBC has been estimated [63]. Recently, the risk
f developing breast cancer for male BRCA1 and BRCA2
utation carriers has been evaluated in the US population by
eans of an analysis of data from 1939 families collected
r
m
ia Modified by Tai et al. [64].
ithin the National Cancer Institute’s Cancer Genetics Net-
ork [64]. Data from this large study show that at all ages,
he cumulative risks of MaleBC are higher in both BRCA1
nd BRCA2 mutation carriers than in non-carriers (Table 3).
he relative risk of developing BC is highest for men in their
hirties and forties and decreases with increasing age. In par-
icular, in BRCA2 mutation carriers the relative risk at age 30
s 22.3 times that at age 70. Both the relative and cumulative
isks are higher for BRCA2 mutation carriers than for BRCA1
utation carriers. In particular, the estimated cumulative risk
f MaleBC at age 70 is 1.2% for BRCA1 mutation carriers and
.8% for BRCA2 mutation carriers (Table 3). Overall, these
bservations demonstrate that BRCA1 mutations are associ-
ted with an increased risk of MaleBC, but such risks are
ubstantially lower than those in BRCA2 mutation carriers.
Male carriers of BRCA1 and BRCA2 mutations are at
ncreased risk of developing several cancer types, includ-
ng prostate and pancreatic cancer. The prostate is the most
onsistently reported site for cancer susceptibility in male
RCA1 and BRCA2 mutation carriers, although the associ-
tion between prostate cancer risk and BRCA2 mutation is
ore consistent. A relative risk (RR) of 1–3 and of 2–5 has
een estimated for BRCA1 and BRCA2 mutation carriers,
espectively, and the RR risk has proved to be greater for men
nder 65 years of age [65,66]. Intriguingly, mutations in the
varian cancer cluster region (OCCR), the central part of the
RCA2 gene associated with a higher risk of ovarian cancer
ompared with breast cancer, are associated with a lower risk
f prostate cancer than mutations outside the OCCR (19.2%
s. 33.6% before the age of 80) [62]. Pancreatic cancer is an
stablished feature of the BRCA2 phenotype. A significant
ncreased risk of pancreatic cancer is reported also in rela-
ives of BRCA1 mutation carriers [63,67]. Overall, a RR of
–3 and of 2–8 has been estimated for BRCA1 and BRCA2
utation carriers, respectively [63,65,67]. Male carriers of
RCA1 and BRCA2 mutations are also at risk of developing
olon and gastric carcinomas, melanoma and non-melanoma
kin cancer. However data to determine the magnitude of
xcess cancer risk at these sites are limited [66].
Overall, these observations indicate that the total cancer
isk to male carriers of BRCA1 and, particularly, BRCA2
utations, is high before the age of 65 and consists mainly
n breast, prostate and pancreatic cancers.
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. Oncogenetic counseling for men at increased
reast cancer risk
At present, oncogenetic counseling is available to women
t increased risk of breast and ovarian cancer. These women
sually have a first-degree FH of cancer and are offered
creening for BRCA1 and BRCA2 mutations. BRCA1/2 genes
esting is an example of susceptibility testing, which is the
ssessment of the future risk determination in an asymp-
omatic individual. To date, attention has focused mainly on
he women belonging to BRCA1 and BRCA2 families and
ittle is known about the impact of genetic testing on men.
No universal guidelines have been established to deter-
ine the population of pts who should be tested for BRCA
utations. General adopted criteria consider families as eli-
ible for BRCA mutations testing if they meet any of the
ollowing classifications: multiple pre-menopausal first or
econd-degree relatives with BC, bilateral BC, ovarian cancer
nd MaleBC. The criteria for testing of men should be similar
o genetic testing criteria for women [66], and the following
ndividuals should therefore be eligible for testing:
men without cancer, if they have a FH of breast or ovar-
ian cancer in first- or second-degree relatives with BC
diagnosed before the age of 50;
men with a diagnosis of breast cancer regardless of FH;
men with a diagnosis of prostate cancer if they have a FH of
breast or ovarian cancer in first- or second-degree relative
with BC diagnosed before age 50;
men of Ashkenazi Jewish descent, since the BRCA genes
mutation prevalence is 2.5% in the general Ashkenazi Jew-
ish population.
To date, fewer men than women have pursued BRCA1 or
RCA2 testing, most likely due to the misinformation about
ancer risk in men. Generally, men have a clear understanding
f genetic testing and often, rather than for their own cancer
isk, their principal motivation for seeking it is concern for
heir families and children, specifically for their daughters
68]. In fact, male carriers of BRCA1 and BRCA2 mutations
ave an increased risk of developing breast, prostate and
ther cancers [66]. There are therefore important manage-
ent implications for male BRCA carriers and there is a need
o promote cancer screening recommendations, particularly
ith regard to breast and prostate cancer, to male carriers of
RCA mutations who are undergoing genetic counseling.
. Histopathological features
About 90% of all male breast tumors prove to be invasive
uctal carcinomas [11]. Since the male breast lacks termi-
al lobules, unless it is exposed to high doses of endogenous
nd/or exogenous estrogens, the lobular histotype accounts
or only 1.5% of invasive cancers, whereas in women more
han 10% of all breast carcinomas are lobular [11,12]. The
obular histotype has been reported in association with Kline-
fi
r
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elter’s syndrome [69]. In situ ductal and lobular in situ
arcinomas account for almost 10% of all male breast car-
inomas [11,70,71]. The vast majority of MaleBCs are low
rade (68–78% G1–2) [72].
In large studies MaleBC has been found to express high
evels of hormone receptors. The estrogen receptors are more
ikely to be positive in MaleBC than in FBC (80–90% vs.
5%) as are the progesterone receptors (73–81% vs. 65.9%),
ith evident therapeutic returns [73–77]. The proportion of
ormone-receptor-expressing tumors increases with age, as
ccurs in post-menopausal women [11]. The expression of
ndrogen receptors ranges from 39 to 95% according to the
arious reports in literature [1,78,79].
With regard to the over-expression of the proto-oncogene
ER2/neu, it should be borne in mind that it is less likely to
e present in MaleBC (about 5%) than in FBC (about 15%)
80,81]. Even though previous studies have reported equiva-
ent over-expression rates for both sexes, it should be noted
hat they were performed prior to the standardization of the
ssessment method, thus leading to a possible overestimation
f the findings [82,83]. Recently, an immunohistochemical
ER2 expression has been found in about 15% of MaleBCs,
onfirmed by FISH in all cases presenting a 3+ Herceptest
84]. Furthermore, it has been observed that the HER2/neu
tatus of the metastatic lesions may differ from that of the
riginal primary tumor [85].
At present, little is known of the immunophenotypic char-
cteristics of MaleBCs stratified according to BRCA1 and
RCA2 mutation status. BRCA2-related MaleBCs seem to
how a significant association with HER2 over-expression
nd have higher histological grades [86]. These data sug-
est that specific phenotypic characteristics, indicative of
ggressive behavior, could be associated with BRCA2-linked
aleBCs.
. Clinical characteristics and diagnostic work-up
The most common clinical sign of breast cancer onset
n men is a painless palpable retroareolar lump [87].
ther initial symptoms may include nipple involvement,
ith retraction and/or ulceration and/or bleeding, and axil-
ary lymphoadenopathies [74,77,87–90]. The association
etween gynecomastia and MaleBC has been studied and
similar incidence has been found in MaleBC pts when
ompared to the general population [6,91].
The majority of pts (over 40%) presents with stage III/IV
isease [1], often due to an early chest wall spread, not only
s a consequence of low public awareness, but also with the
carcity of male breast parenchyma. It is interesting to note
hat the proportion of advanced stage disease reaches 50–60%
hen North African series are involved [92].
Clinically suspicious lesions referred for imaging should
rst be evaluated with mammography and with ultrasonog-
aphy scans to select pts who will undergo to FNA or core
iopsy (Fig. 1). Mammography can identify malignant breast
L. Ottini et al. / Critical Reviews in Oncolo
Fig. 1. Algorithm for the management of suspicious male breast mass.
US = ultrasonography; BC = breast cancer; IHC = immunohistochemistry;
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A = locally advanced disease; Neo-Adj = neo-adjuvant treatment;
1 = metastatic disease; * = post-op treatment in Fig. 2.
umors with a sensitivity of 92–100% and a specificity of 90%
93–95]. US of the axillary region could be helpful for stag-
ng as long as more than 50% of pts have positive axillary
odes at diagnosis [74].
. Prognostic evaluation
Overall, men experience a worse prognosis than women
96], probably due to an advanced stage at diagnosis together
ith the higher age of male patients often leading to the coex-
stence of serious comorbidities. The overall 5- and 10-year
urvival rate of MaleBC patients are around 60 and 40%,
espectively [11]. Nevertheless, when male or FBC pts are
atched with respect to age and stage, no significant differ-
nce in terms of DFS or OS between the sexes is observed
97].
The number of histologically positive axillary nodes and
he tumor diameter are significant prognostic factors [11].
he higher the number of lymph node metastases, the more
nfavorable the prognosis will be. In fact, the survival rates
t 5 years has been reported to be 90% for patients with node
egative disease, 73% for those with 1–3 positive nodes and
5% for the group with 4 or more involved nodes [98]. It has
o be mentioned that axillary nodes involvement has been
eported in about the 50–60% of cases [99].
Another negative prognostic factor is the advanced age at
he time of diagnosis, since the increased presence of comor-
idities may limit the possibility of treatment [77,100]. Thus,
he disease-specific survival (DSS) rates should be considered
74,98]. In a large French series, 5- and 10-year OS rates of 65
nd 38%, respectively, were reported, whereas the DSS rates
p
fl
t
cgy/Hematology 73 (2010) 141–155 147
ere 74 and 51%, respectively. In fact, only 113 (60.5%) out
f the 187 deceased pts, died of breast cancer [74].
. Locoregional treatments for male breast cancer
To date there are no published data from prospective ran-
omized trials supporting a specific therapeutic approach in
aleBC. Most of the information regarding locoregional
reatment derives from retrospective studies or those per-
ormed by individual institutions, with all the potential biases
eriving from an analysis of data collected over a time span
f several decades. This means, therefore, that almost all the
reatment strategies that have been progressively adopted in
aleBC are based upon data resulting from female studies.
review of literature clearly shows that changes in treating
aleBC mirror the evolution of FBC care.
.1. Surgery
Surgery is the cornerstone of treatment of MaleBC pts
75]. Until the 1970s, as for FBC, radical mastectomy was
he treatment of choice for MaleBC; this approach was sub-
equently progressively substituted by less invasive surgical
rocedures, such as modified radical mastectomy, according
o lesion extension [75,101,102].
Initial reports suggested that a less invasive approach
ight possibly have little effect on the patient’s outcome
103–105]. More recently, in a retrospective study with 397
aleBC cases, this topic has been reopened by Cutuli et al.,
ho have reported that radical mastectomy is of no more
alue than modified radical mastectomy in terms of local
elapse [74].
Since breast conservation has become the standard for
he surgical management of FBC [106–110] new interest in
inimally invasive surgical procedures has also arisen in the
reatment in male pts.
Conservative breast surgery followed by radiotherapy,
roposed in selected pts for the treatment of small tumors,
as produced encouraging results, although there may be
everal technical difficulties when the procedure is used in
ales [111]; in fact, a larger tumor size and a higher rate
f chest wall infiltration are found compared to female pts
112]. Moreover the usual central or retroareolar localization
f the primary tumor in men, together with the paucity of the
ale breast parenchyma, makes a partial resection difficult to
e planned. Nevertheless, in selected situations, for example
hen the breast tumor is associated with gynecomastia, even
lumpectomy could be a rational approach [111].
Radical mastectomy often leads to widespread skin
emoval, consequently causing problems in the management
f the chest wall defect. Different options have been pro-
osed such as the use of a transverse thoracoepigastric skin
ap [113]. Other authors have suggested that a transverse rec-
um abdomini myocutaneous (TRAM) flap may be the best
hoice for male breast reconstruction, not only because it is
148 L. Ottini et al. / Critical Reviews in Oncology/Hematology 73 (2010) 141–155
F herapy;
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cig. 2. Algorithm for the treatment of early male breast cancer. RT = radiot
actor receptor 2; T = tamoxifen; H = trastuzumab; CT = chemotherapy; * = c
ble to replace the missing skin and fat but also because it
ay be a source of hair-bearing skin similar to that of the
ale breast [114]. When the surgical wound is closed, the
ipple can be reconstructed surgically or simply tattooed to
estore the body image.
As for breast surgery, the surgical management of axil-
ary lymph nodes has also undergone changes over the past
ears. Since axillary node involvement is one of the most
elevant prognostic variables in MaleBC as in FBC [11], axil-
ary lymph node dissection has been performed as part of
he adjuvant treatment, but it is consistently associated with
any late complications (i.e. lymphedema, paresthesias and
educed motility of the upper limb) [115].
Since several studies in FBC have shown that sentinel
ymph node biopsy (SLNB) can reliably predict the status
f axillary nodal involvement, so preventing useless larger
issections and ameliorating the quality of life [116], a
inimally invasive approach has also became the standard
reatment for men pts [117,118].
The first report regarding SLNB in a man with BC, was
ublished by Hill et al. from the Memorial Sloan Kettering
ancer Center [119]. Larger single institution series, overall
ncluding <200 pts, have subsequently been collected by the
eading American and European centers for breast cancer
are, suggesting that SLNB in MaleBC pts is an extremely
ccurate tool providing a sentinel lymph node detection rate
lose to 100% [120–123]. The use of this technique could be
ndicated in pts with tumor size <2.5 cm and without clinical
vidence of axillary node involvement [124].
.2. Adjuvant radiotherapy
As MaleBC frequently presents at an advanced stage
ith early nodal involvement, locoregional relapse rates after
urgery alone are quite high. In a comparative study published
n the late-1990s by Scott-Conner, analyzing stage-specific
ifferences in contemporary treatment strategies for highly
omparable breast cancer pts of both sexes treated between
985 and 1992, it was reported that radiotherapy after surgery
as preferentially given to males [125].
a
e
t
wN = node involvement; ER = estrogen receptor; HER2 = epidermal growth
r CT according to risk level.
Nevertheless, a subsequent large retrospective analysis of
aleBCs diagnosed between 1995 and 2005 have showed
hat, to date, male pts are more likely not to receive adjuvant
adiotherapy compared to women [112].
Unfortunately, it is difficult to properly evaluate the real
mpact of adjuvant radiotherapy in MaleBC pts in terms of
FS and OS since most of the papers dealing with the ques-
ion are statistically underpowered [96,126,127].
Notwithstanding this, several retrospective single institu-
ion studies have reported an excellent rate of local control
fter radiotherapy. Stranzl et al. have obtained a local control
ate of 96.8% on a cohort of 31 pts who underwent post-
astectomy adjuvant radiation with a 5-year DSS and DFS
f 84% and 73%, respectively [128]. Similar results have
een reported by Zabel et al. and Ober et al., the former
ith a local control rate of 96% after postoperative radio-
herapy, the latter found that 5- and 10-year rates of local
ontrol were 90 and 85%, respectively, on a series of 41 pts
129,130].
Furthermore, these encouraging results concur with the
wo largest studies published so far. The first one by Cutuli
t al. collected 690 pts coming from 20 French institutions
ver a time span of 30 years. In this series, the overall rate
f locoregional relapse among the 496 evaluable pts was
.5%, with a significant difference between irradiated and
on-irradiated pts (7.3% vs. 13%, respectively) [131]. In the
econd one, on a historical cohort of 428 pts, Ribeiro et al.
emonstrated a significant difference in 5-year DFS rates
etween pts receiving radical mastectomy alone or simple
astectomy plus radiotherapy (44.6% vs. 77.2%, respec-
ively) [77]. Other studies have failed to show a significant
mpact of RT on local recurrence rates [89].
The drawbacks of all the cited studies should be borne in
ind when planning the therapeutic strategy for pts treated
utside controlled trials. All these retrospective data, in fact,
ollected over several decades, are not able to take into
ccount the huge technical changes in RT planning and deliv-
ry. Moreover, RT can be used in association with various
ypes of surgery on both the breast and the axilla and also
ith a wide range of systemic adjuvant treatments, hence the
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ame guidelines generally accepted for FBC can be followed
1,89,99,132–134].
Adjuvant radiotherapy should be mandatory after breast-
onserving surgery and, on the chest wall, after mastectomy
n cases of close or positive margins and tumors larger than
cm with areola, skin or pectoral muscle involvement. More-
ver, histological parameters, such as lymph-vascular space
nvasion, high tumor proliferation rates, high grade, multifo-
ality and nodal involvement should strongly recommend RT
n primary site [124,127,135].
It has been proven that in male pts too, axillary nodal
nvolvement is the most accurate predictor of locoregional
ailure [127,136] as well as of shorter DFS [75,101] and
S [89,137,138], which indicates that the fixed number of
involved axillary nodes requiring additional axillar irradi-
tion in female pts might also be used for male pts [139].
imilarly, supraclavicolar area irradiation should be consid-
red with 4 or more nodes involved.
0. Adjuvant chemotherapy
Whereas reliable data support the use of adjuvant CT in
omen [140], the few available data regarding men suggest
hat such strategy might be beneficial even in this subpopu-
ation [141].
Great caution is required given the possibility of increased
oxicities due to comorbidities and older age at diagnosis.
Several retrospective series have suggested that the use of
djuvant CT in male pts is associated with a reduced risk of
elapse [142–144].
In 1987, Bagley et al. published the results of a small,
rospective study involving 24 men with stage II breast car-
inoma treated with adjuvant CMF and reported a 5-year
urvival rate of over 80% [145]. Yildirim and Berberoglu
ave found an increase of 5-year survival rate in 121 men
reated with different regimens [144].
Since MaleBC is a rare disease, it is hardly possible to
lan and carry out large randomized studies; nevertheless,
iven the confirmed results regarding FBC and the posi-
ive experiences in men, both men and women could share
he same guidelines for adjuvant treatment [146]. So that,
hemotherapy should be used in the absence or doubt about
ndocrine-responsiveness and the taxanes may be considered
hen lymph nodes are involved. Regarding the use of adju-
ant trastuzumab, since no specific data exist, its use should
e considered according to patients’ and tumor characteris-
ics, following FBC guidelines (Fig. 2).
1. Adjuvant hormonal therapyAs previously mentioned, MaleBC expresses hormone
eceptors in about 90% of cases, which makes adjuvant hor-
one treatment a basic part of the therapeutic management
f the disease (Fig. 2). A great many retrospective studies
i
c
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ave, in fact, evaluated the usefulness of tamoxifen, first in
he metastatic setting [3], where it has proved to be extremely
ctive, and subsequently in the adjuvant setting, where it has
een associated with a reduction of the relapse and mortality
ates [75,77,147,148]. Goss et al. in particular have reported
significant increase, both in DFS and OS, in a series of
aleBC pts treated with hormone therapy, even though often
dministered for <2 years [75]. Another study including 39
en with stage II/III BC has shown a 5-year survival rate
f 61% in pts treated with adjuvant tamoxifen for 1 or 2
ears, vs. 44% in the control cases [77]. Interestingly, in both
hese experiences the duration of the adjuvant therapy was
horter than the normal standard of 5 years; both these studies,
herefore, might even have underestimated the real benefits
eriving from adjuvant tamoxifen.
Moreover, in a recent British observational study, per-
ormed between 2002 and 2003 to evaluate the management
f men with breast carcinoma, it has been noted that 126
ts out of the considered 161 (78%) had received adjuvant
amoxifen [149].
Tamoxifen has proved to lead to an increase in survival
ates in women with hormone-responsive disease and to date
s generally considered the standard adjuvant treatment for
ormone-dependent MaleBC. The tolerance of the drug has
ot been sufficiently studied in men; its main side effects
re deep venous thrombosis, reduction of libido, impotence,
ood changes and hot flushes [150].
With regard to aromatase inhibitors, even fewer studies
ave been performed to evaluate their role in the adjuvant
etting; in fact, preclinical data have led to doubts regard-
ng their usefulness. When used in healthy male volunteers,
nastrozole has not proved to bring about the complete estro-
enic suppression it usually provides in women: only a
0% reduction of estradiol plasma levels associated with an
ncrease in testosterone levels in the 58% of cases has been
bserved [151]. On the contrary, encouraging results have
een obtained in two pts treated with letrozole for metastatic
isease: an objective response has been obtained in both cases
one with complete response) [152,153].
To date, the use of aromatase inhibitors and/or GnRH ana-
ogues cannot be included in the adjuvant treatment strategy
or men with breast cancer.
2. Neoadjuvant therapies
The main indications for the use of neoadjuvant treatments
re the presence of an ulcerated neoplasia, its fixation to the
urrounding tissues, a state of advanced lymph node involve-
ent and the possibility of avoiding surgical treatment which
ould modify the body structure [134]. A further advantage
s that it makes it possible to observe the drug efficacy in vivo:
t is now known that those pts who achieve a histopathological
omplete response to neoadjuvant therapy generally have a
ore favorable prognosis. Since no specific data on this topic
or MaleBC exist, FBC guidelines should be followed man-
150 L. Ottini et al. / Critical Reviews in Oncolo
Fig. 3. Algorithm for the treatment of locally advanced inoperable
male breast cancer. LABC = locally advanced breast cancer; Neo-
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Odj = neo-adjuvant treatment; ER = estrogen receptor; HT = hormonal
herapy; CT = chemotherapy; H* = trastuzumab depending on HER2 status;
T = radiotherapy.
ging eventual peculiar situations. The choice of treatment
epends essentially on the biological features of the tumor
Fig. 3).
3. Treatment of metastatic disease
In the past, the traditional management of metastatic
aleBC consisted in surgical interventions causing hormonal
tatus modifications, such as orchiectomy, adrenalectomy
r hypophysectomy, which did, in fact, lead to a positive
esponse in 55–80% of the cases, depending on the performed
rocedure [1,154–158]. Obviously, these surgical approaches
ere effective only in the majority of pts with hormone-
esponsive breast carcinomas. Nowadays these methods have
iven way to various types of additive hormone treatment, the
ost important being tamoxifen, which leads to a response
n about 50% of cases [159]. There have been reports of
ven complete response to LH–RH analogues, with or with-
ut antiandrogens [160–162]. Other possibilities to take into
onsideration include androgens, progestins, corticosteroids
nd high doses of estrogens, in order to obtain response rates
anging from 32 to 75%, according to the chosen drug [1].
he role of fulvestrant remains undetermined for MaleBC
ts.
As already mentioned in the section regarding adjuvant
herapy, the role of aromatase inhibitors in MaleBC has not
et been sufficiently evaluated and is therefore still not fully
nderstood, although encouraging results have been obtained
rom single institution experiences [152,153,163].
In spite of the fact that the mean onset age in males
s higher than in females, this alone cannot be considered
s a valid criterion for excluding chemotherapeutic man-
gement; treatment choice should depend upon the clinical
nd biological features. At the present time, chemotherapy
hould be addressed to hormone-refractory disease, to young
en and to cases of aggressive tumors, for example those
ith visceral metastases. It should be borne in mind that
hemotherapy might also have a significant palliative effect
A
agy/Hematology 73 (2010) 141–155
164]. Since very few reports can be retrieved from litera-
ure, there is no standard chemotherapeutic regimen, with
esponse rates ranging from the 13% of 5-fluorouracile alone
o the 67% of the combination of 5-fluorouracile, doxorubicin
nd cyclophosphamide [159].
With regard to male pts with HER2/neu over-expressing
umors, they should be treated with trastuzumab, on the basis
f data coming from FBC both in the adjuvant and in the
etastatic settings [165–168].
ractice points
Major risk factors for the development of MaleBC include
clinical disorders carrying hormonal imbalances, radiation
exposure and a strong FH for BC.
MaleBC can be linked to mutations in BRCA or in low-
penetrance genes (i.e. CHEK-2).
Men with BC should be referred for genetic counseling
and potential genetic testing.
Most MaleBCs are advanced stage ductal invasive carci-
nomas.
MaleBC expresses hormone receptors in about 90% of
cases and is less likely to over-express HER2/neu than
FBC.
Locoregional approaches include surgery and RT depend-
ing upon the initial clinical presentation.
Systemic treatment must be administered according to the
tumor biology:
◦ Tamoxifen is the recommended therapeutic option for
hormone sensitive MaleBCs, either as adjuvant or
metastatic first-line treatment. Data on the efficacy of
other hormonal therapies are not yet definitive, even
though positive experiences have been reported.
◦ CT should be prescribed in the absence or doubt about
endocrine-responsiveness.
◦ HER2/neu over-expressing tumors should be treated
with trastuzumab.
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